Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Lower respiratory tract infections,Acute bacterial sinusitis,Otitis media,Urinary tract infections,Skin and skin structure infections,Bone and joint infections,Intra-abdominal infections,Dental infections
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Amoxicillin undergoes partial hepatic metabolism via hydrolysis. Clavulanate is extensively metabolized in the liver, primarily by hydrolysis and conjugation.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
Amoxicillin: ~20% (mainly albumin); Clavulanate: ~25% (albumin).
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
Amoxicillin: ~0.3-0.4 L/kg; Clavulanate: ~0.3 L/kg. Distributes into tissues, not CSF unless inflamed.
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Oral: ~80-90% for amoxicillin; ~60-75% for clavulanate. Enhanced with food.
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
For Cr Cl 10-30 m L/min: 250-500 mg amoxicillin component every 12 hours. For Cr Cl <10 m L/min: 250-500 mg amoxicillin component every 24 hours. Hemodialysis: 250-500 mg every 24 hours, give additional dose during and after dialysis.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No specific dose adjustment recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C); consider alternative therapy or reduced dosing, but no formal guidelines.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
For children >3 months: 25-45 mg/kg/day of amoxicillin component divided every 12 hours (based on 200 mg/28.5 mg per 5 m L suspension) or 20-40 mg/kg/day divided every 8 hours (based on 125 mg/31.25 mg per 5 m L suspension). For severe infections, up to 90 mg/kg/day of amoxicillin component divided every 12 hours (using 400 mg/57 mg per 5 m L suspension).
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
Initiate at lower end of dosing range due to increased risk of renal impairment. Monitor renal function and adjust dose based on creatinine clearance as per renal adjustment guidelines.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
No FDA boxed warning.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) in patients with penicillin allergy,Clostridioides difficile-associated diarrhea,Hepatic toxicity (elevated liver enzymes, hepatitis, cholestatic jaundice) more common in elderly and with prolonged use,Renal impairment requires dose adjustment,Risk of superinfection with prolonged therapy,Skin rash can occur in patients with mononucleosis
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
History of anaphylactic reaction to penicillins or cephalosporins,Previous cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Concurrent use with disulfiram or probenecid (relative)
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
May be taken with or without food; food enhances absorption; avoid ingestion with high-dose clavulanate? (no significant interaction); no specific food restrictions; milk-containing products do not interact significantly.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Use during first trimester is considered safe if clinically indicated. During second and third trimesters, no known fetal risks. However, avoid use near term due to potential for neonatal kernicterus (theoretical risk from high doses, but not confirmed).
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Amoxicillin and clavulanate are excreted into breast milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding by AAP; risk of infant sensitization, diarrhea, or thrush. Use with caution in infants with history of penicillin allergy.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
Pharmacokinetic changes in pregnancy (increased renal clearance, expanded plasma volume) may require dose adjustments: total daily dose typically remains same but dosing interval may need to be shortened (e.g., every 6-8 hours instead of every 12 hours) for severe infections; monitor clinical response. No standard recommendation for routine adjustment; base on severity and renal function.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Use weight-based dosing for pediatric patients; reconstitute oral suspension with appropriate amount of water; administer at start of meal to reduce GI upset; check renal function before dosing; avoid in patients with mononucleosis due to risk of maculopapular rash; higher doses of clavulanate may cause diarrhea; intravenous infusion over 30-40 minutes; consider penicillin allergy cross-reactivity; not effective against MRSA; requires dose adjustment in Cr Cl <30 m L/min.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
Take this medication exactly as prescribed, usually every 12 hours.,Take with food to reduce stomach upset and improve absorption.,Complete the full course even if you feel better.,Shake the oral suspension well before each use.,Store oral suspension in refrigerator, discard after 10 days.,Report severe diarrhea, rash, or signs of allergy immediately.,May cause diarrhea; do not treat without consulting doctor.,Inform your doctor if you are pregnant, breastfeeding, or have liver disease.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMOXICILLIN AND CLAVULANATE POTASSIUM vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
AMOXICILLIN AND CLAVULANATE POTASSIUM is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMOXICILLIN AND CLAVULANATE POTASSIUM and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMOXICILLIN AND CLAVULANATE POTASSIUM is: 500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMOXICILLIN AND CLAVULANATE POTASSIUM and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMOXICILLIN AND CLAVULANATE POTASSIUM is classified as Category A/B. Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Us. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.